British Journal of Cancer

Article	Citations
Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial	173
Advancing radiomics from contrast-enhanced mammography in breast cancer	157
Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours	138
Investigation of the gut microbiome, bile acid composition and host immunoinflammatory response in a model of azoxymethane-induced colon cancer at discrete timepoints	137
Surveillance after childhood cancer: are survivors with an increased risk for cardiomyopathy regularly followed-up?	135
Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma	102
Correction to: Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort	102
Correction to: EGFR/Ras-induced CCL20 production modulates the tumour microenvironment	100
Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours	99
Integrated genomic and transcriptomic analysis reveals the activation of PI3K signaling pathway in HPV-independent cervical cancers	96
A very-hot food and beverage thermal exposure index and esophageal cancer risk in Malawi and Tanzania: findings from the ESCCAPE case–control studies	95
Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC)	89
Targeting mitochondrial oxidative phosphorylation: lessons, advantages, and opportunities	89
Mismatch repair markers in preoperative and operative endometrial cancer samples; expression concordance and prognostic value	89
Comprehensive assessment of actionable genomic alterations in primary colorectal carcinoma using targeted next-generation sequencing	88
The EXO1/Polη/Polι axis as a promising target for miR-3163-mediated attenuation of cancer stem-like cells in non-small cell lung carcinoma	88
Fibroblast growth factor signalling influences homologous recombination-mediated DNA damage repair to promote drug resistance in ovarian cancer	86
Years of life lost due to cancer in the United Kingdom from 1988 to 2017	83
Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study)	82
VinCaP: a phase II trial of vinflunine in locally advanced and metastatic squamous carcinoma of the penis	81
Normal weight obesity, circulating biomarkers and risk of breast cancer: a prospective cohort study and meta-analysis	80
Extruded small extracellular vesicles: splinters of circulating tumour cells may promote cancer metastasis?	80
PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer	80
Hepatitis B virus X protein promotes MAN1B1 expression by enhancing stability of GRP78 via TRIM25 to facilitate hepatocarcinogenesis	79
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3	75

Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer	75
Hit it hard: qualitative patient perspectives on the optimisation of immune checkpoint inhibition	74
Proactive breast cancer risk assessment in primary care: a review based on the principles of screening	73
Cancer therapy with decreased SARS-CoV-2 infection rates in cancer patients	71
DRP1 inhibition-mediated mitochondrial elongation abolishes cancer stemness, enhances glutaminolysis, and drives ferroptosis in oral squamous cell carcinoma	69
Navigating therapeutic strategies: HPV classification in head and neck cancer	68
Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate	67
Impact of clonal TP53 mutations with loss of heterozygosity on adjuvant chemotherapy and immunotherapy in gastric cancer	66
Genomic ALK alterations in primary and relapsed neuroblastoma	66
The prognostic and biology of tumour-infiltrating lymphocytes in the immunotherapy of cancer	65
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours	64
Metabolic adaptations in prostate cancer	63
Metastasis-associated fibroblasts in peritoneal surface malignancies	62
Clinicopathological and molecular characteristics of RSPO fusion-positive colorectal cancer	61
Fibroblast activation protein-targeted near-infrared photoimmunotherapy depletes immunosuppressive cancer-associated fibroblasts and remodels local tumor immunity	60
The mental health impacts of receiving a breast cancer diagnosis: A meta-analysis	60
Identification of increased dedifferentiation along the Prom1+ cancer cells in Müllerian adenosarcoma with sarcomatous overgrowth	59
Assessments of social vulnerability on laryngeal cancer treatment & prognosis in the US	59
CD20 expression, TrkB activation and functional activity of diffuse large B cell lymphoma-derived small extracellular vesicles	59
Long-term trends in incidence, characteristics and prognosis of screen-detected and interval cancers in women participating in the Dutch breast cancer screening programme	58
Circulating tumour DNA monitoring and early treatment for relapse: views from patients with early-stage melanoma	57
Hypoxia- and Postirradiation reoxygenation-induced HMHA1/ARHGAP45 expression contributes to cancer cell invasion in a HIF-dependent manner	57
Risk of subsequent primary oral cancer in a cohort of 69,460 5-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study	57
Somatic hits in mismatch repair genes in colorectal cancer among non-seminoma testicular cancer survivors	56
Clinical outcome and prognostic factors for Asian patients in Phase I clinical trials	56
The impact of the first 2 years of the COVID-19 pandemic on breast cancer diagnoses: a population-based study in England	55
Prognostic relevance of the neurological symptom burden in brain metastases from breast cancer	54
Adolescent dietary patterns in relation to later prostate cancer risk and mortality in the NIH-AARP Diet and Health Study	53
DNA repair-dependent immunogenic liabilities in colorectal cancer: opportunities from errors	53
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer	53
Albendazole inhibits colon cancer progression and therapy resistance by targeting ubiquitin ligase RNF20	53
Cancer in Costello syndrome: a systematic review and meta-analysis	52
Multistate models for the natural history of cancer progression	52
Progress and priorities in reducing the time to cancer diagnosis	52
Prognostic significance of PET/CT and its association with immuno-genomic profiling in oesophageal squamous cell carcinoma treated with immunotherapy plus chemoradiotherapy: results from a phase II st	52
Preclinical study of 212Pb alpha-radioimmunotherapy targeting CD20 in non-Hodgkin lymphoma	52
Identification of MYCN non-amplified neuroblastoma subgroups points towards molecular signatures for precision prognosis and therapy stratification	51
Oxaliplatin induces pyroptosis in hepatoma cells and enhances antitumor immunity against hepatocellular carcinoma	50
Optimizing adjuvant treatment strategies for non-pancreatic periampullary cancers	50
Implications of obesity and insulin resistance for the treatment of oestrogen receptor-positive breast cancer	50
Regional variations in hepatocellular carcinoma incidence, routes to diagnosis, treatment and survival in England	50
The HLA ligandome of oropharyngeal squamous cell carcinomas reveals shared tumour-exclusive peptides for semi-personalised vaccination	46
A comprehensive appraisal of HER2 heterogeneity in HER2-amplified and HER2-low colorectal cancer	46
Evidence into practice: a national cohort study of NICE-recommended oncological drug therapy utilisation among women diagnosed with invasive breast cancer in England	46
Serum 25-hydroxyvitamin D concentrations and colorectal cancer incidence in adults with type 2 diabetes	45
Nutritional status, body composition and chemotherapy dosing in children and young people with cancer: a systematic review by the SIOP nutrition network	45
The Glasgow Microenvironment Score and risk and site of recurrence in TNM I–III colorectal cancer	45
Changes in circulating exosome molecular profiles following surgery/(chemo)radiotherapy: early detection of response in head and neck cancer patients	44
Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer	44
Therapeutic impact of BET inhibitor BI 894999 treatment: backtranslation from the clinic	43

Emerging nanomedical strategies for direct targeting of pediatric and adult diffuse gliomas	43
PTBP1 drives c-Myc-dependent gastric cancer progression and stemness	43
Neoadjuvant chemotherapy is noninferior to chemoradiotherapy for early-onset locally advanced rectal cancer in the FOWARC trial	43
The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy	43
Long-term use of antihypertensive medications, hypertension and colorectal cancer risk and mortality: a prospective cohort study	42
EEF1A2 promotes HIF1A mediated breast cancer angiogenesis in normoxia and participates in a positive feedback loop with HIF1A in hypoxia	42
A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)	41
A systematic review of microbial markers for risk prediction of colorectal neoplasia	41
A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study	41
A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer	41
Deep learning analysis of histopathological images predicts immunotherapy prognosis and reveals tumour microenvironment features in non-small cell lung cancer	41
Tissue factor in cancer-associated thromboembolism: possible mechanisms and clinical applications	40
Introduction and impact of routine whole genome sequencing in the diagnosis and management of sarcoma	40
Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150	40
Expression and functions of long non-coding RNA NEAT1 and isoforms in breast cancer	40
Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients	39
Characterisation of FLT3 alterations in childhood acute lymphoblastic leukaemia	39
Efficacy and quality of life for FOLFOX/bevacizumab +/− irinotecan in first-line metastatic colorectal cancer—final results of the AIO CHARTA trial	38
Correction: Differential cellular origins of the extracellular matrix of tumor and normal tissues according to colorectal cancer subtypes	38
APR-246 induces apoptosis and enhances chemo-sensitivity via activation of ROS and TAp73-Noxa signal in oesophageal squamous cell cancer with TP53 missense mutation	38
Consultations for clinical features of possible cancer and associated urgent referrals before and during the COVID-19 pandemic: an observational cohort study from English primary care	37
Pathological complete response, category change, and prognostic significance of HER2-low breast cancer receiving neoadjuvant treatment: a multicenter analysis of 2489 cases	37
Clinical efficacy and immune response of neoadjuvant camrelizumab plus chemotherapy in resectable locally advanced oesophageal squamous cell carcinoma: a phase 2 trial	37
A multimodal imaging study to highlight elastin-derived peptide pro-tumoral effect in a pancreatic xenograft model	36
Thinking inside the box: intracellular roles for complement system proteins come into focus	36
Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)—a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma	36
Exploiting dietary fibre and the gut microbiota in pelvic radiotherapy patients	36
Routes to diagnosis for hepatocellular carcinoma patients: predictors and associations with treatment and mortality	36
High-throughput precision MRI assessment with integrated stack-ensemble deep learning can enhance the preoperative prediction of prostate cancer Gleason grade	36
Circulating tumour DNA and its clinical utility in predicting treatment response or survival in patients with metastatic colorectal cancer: a systematic review and meta-analysis	36
Immune evasion in lung metastasis of leiomyosarcoma: upregulation of EPCAM inhibits CD8+ T cell infiltration	35
Manassantin A inhibits tumour growth under hypoxia through the activation of chaperone-mediated autophagy by modulating Hsp90 activity	35
Correction: Modelled mortality benefits of multi-cancer early detection screening in England	35
Cancer risk in individuals with polydactyly: a Swedish population-based cohort study	35
The prognostic value of MEK pathway–associated estrogen receptor signaling activity for female cancers	35
Novel prognostic implications of complement activation in the tumour microenvironment for de novo metastatic BRAF V600E mutant colorectal cancer	35
Alkaline phosphatase decline and pain response as predictors of overall survival benefit in patients treated with radium-223: a post hoc analysis of the REASSURE study	35
The in vitro dynamics of pseudo-vascular network formation	34
A UK prospective multicentre decision impact, decision conflict and economic evaluation of the 21-gene assay in women with node+ve, hormone receptor+ve, HER2-ve breast cancer	34
Correction: Targeting oncogenic microRNAs from the miR-371~373 and miR-302/367 clusters in malignant germ cell tumours causes growth inhibition through cell cycle disruption	34
Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin	34
MET exon 14 skipping mutation drives cancer progression and recurrence via activation of SMAD2 signalling	34
Oesophageal cancer awareness and anticipated time to help-seeking: results from a population-based survey	34
A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer	34
Transcriptomic and functional analyses reveal a tumour-promoting role for the IL-36 receptor in colon cancer and crosstalk between IL-36 signalling and the IL-17/ IL-23 axis	33
Chromatin accessibility uncovers KRAS-driven FOSL2 promoting pancreatic ductal adenocarcinoma progression through up-regulation of CCL28	33
The mediating role of combined lifestyle factors on the relationship between education and gastric cancer in the Stomach cancer Pooling (StoP) Project	33
What do women think about having received their breast cancer risk as part of a risk-stratified NHS Breast Screening Programme? A qualitative study	33
A metabolomic analysis of adiposity measures and pre- and postmenopausal breast cancer risk in the Nurses’ Health Studies	33
Cannabinoids induce cell death in leukaemic cells through Parthanatos and PARP-related metabolic disruptions	33
Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer	33
Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions	32
Immune checkpoint inhibitor combinations—current and emerging strategies	32
Hyperglycaemia induces metabolic reprogramming into a glycolytic phenotype and promotes epithelial-mesenchymal transitions via YAP/TAZ-Hedgehog signalling axis in pancreatic cancer	32
Molecular pathways in post-colonoscopy versus detected colorectal cancers: results from a nested case–control study	32
Integrated proteomics and scRNA-seq analyses of ovarian cancer reveal molecular subtype-associated cell landscapes and immunotherapy targets	32
The prognostic impact of peritoneal tumour DNA in gastrointestinal and gynaecological malignancies: a systematic review	32
Cost-effectiveness of one-off upper abdominal CT screening as an add-on to lung cancer screening in England	32
Confidence bands in survival analysis	32
Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer	32
Glycometabolic reprogramming-mediated proangiogenic phenotype enhancement of cancer-associated fibroblasts in oral squamous cell carcinoma: role of PGC-1α/PFKFB3 axis	32
Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours	32
Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors	31
Hypoxia does not predict lack of benefit from adjuvant radiotherapy for patients with early stage breast cancer	31
Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology – an analysis of the closed cohorts of a multicentre prospective study	31
Correction: Chromatin profile-based identification of a novel ER-positive breast cancer subgroup with reduced ER-responsive element accessibility	31
50 years on and still very much alive: ‘Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics’	31
DNA ploidy and PTEN as biomarkers for predicting aggressive disease in prostate cancer patients under active surveillance	31
VIVA1: a more invasive subclone of MDA-MB-134VI invasive lobular carcinoma cells with increased metastatic potential in xenograft models	31
Reply to Dr. Rafael Rosell: Shedding some light on the unresolved issue of YAP1 Ser397 phosphorylation in cancer	31
UK Biobank: a globally important resource for cancer research	31
Sodium nitrite orchestrates macrophage mimicry of tongue squamous carcinoma cells to drive lymphatic metastasis	31
Non-muscle-invasive micropapillary bladder cancer has a distinct lncRNA profile associated with unfavorable prognosis	31
Regulatory non-coding somatic mutations as drivers of neuroblastoma	31
Resectability, conversion, metastasectomy and outcome according to RAS and BRAF status for metastatic colorectal cancer in the prospective RAXO study	30
Identification of diagnostic biomarkers in prostate cancer-related fatigue by construction of predictive models and experimental validation	30
HECTD3 regulates the tumourigenesis of glioblastoma by polyubiquitinating PARP1 and activating EGFR signalling pathway	30
Preferences for multi-cancer tests (MCTs) in primary care: discrete choice experiments of general practitioners and the general public in England	30
The role of genetic predisposition in cardiovascular risk after cancer diagnosis: a matched cohort study of the UK Biobank	30
EIF4A3-negatively driven circular RNA β-catenin (circβ-catenin) promotes colorectal cancer progression via miR-197-3p/CTNND1 regulatory axis	30

COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer	30
Correction to: The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care	30
Targeting oncogenic microRNAs from the miR-371~373 and miR-302/367 clusters in malignant germ cell tumours causes growth inhibition through cell cycle disruption	30
Nonrandomised controlled trial in recurrent glioblastoma patients: the promise of autologous tumour lysate-loaded dendritic cell vaccination	30
Breast cancer hypoxia in relation to prognosis and benefit from radiotherapy after breast-conserving surgery in a large, randomised trial with long-term follow-up	30
Prognostic significance of pathogenic variants in BRCA1, BRCA2, ATM and PALB2 genes in men undergoing hormonal therapy for advanced prostate cancer	30
CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancer	30
Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status	30
Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial	30
MicroRNAs as biomarkers for prostate cancer prognosis: a systematic review and a systematic reanalysis of public data	29
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma	29
Single-cell sequencing of PIT1-positive pituitary adenoma highlights the pro-tumour microenvironment mediated by IFN-γ-induced tumour-associated fibroblasts remodelling	29
Cancer-associated fibroblasts expressing fibroblast activation protein and podoplanin in non-small cell lung cancer predict poor clinical outcome	29
Impact of obesity on chemotherapy dosing of carboplatin and survival of women with ovarian cancer	29
Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations	29
Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk	29
Postdiagnosis physical activity is associated with improved survival in prostate cancer patients treated with surgery but not with radiation therapy	29
Health benefits and harms of mammography screening in older women (75+ years)—a systematic review	29
Impact of the selective A2AR and A2BR dual antagonist AB928/etrumadenant on CAR T cell function	29
A systematic review and meta-analysis of toxicity and treatment outcomes with pharmacogenetic-guided dosing compared to standard of care BSA-based fluoropyrimidine dosing	29
Repositioning canakinumab for non-small cell lung cancer—important lessons for drug repurposing in oncology	29
Stroma AReactive Invasion Front Areas (SARIFA) and the tumour immune microenvironment in colorectal cancer	29
Plasma extracellular vesicle circRNA signature and resistance to abiraterone in metastatic castration-resistant prostate cancer	29
Exosomal transfer of miR-181b-5p confers senescence-mediated doxorubicin resistance via modulating BCLAF1 in breast cancer	29
Obituary – Margaret Wilcox	28
Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group	28
The National COVID Cancer Antibody Survey: a hyper-accelerated study proof of principle for cancer research	28
Editorial Expression of Concern: Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential	28
Imipridones inhibit tumor growth and improve survival in an orthotopic liver metastasis mouse model of human uveal melanoma	28
Comparison of methods for cancer stem cell detection in prognosis of early stages NSCLC	28
Mutation of the proline P81 into a serine modifies the tumour suppressor function of the von Hippel–Lindau gene in the ccRCC	28
Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?	28
Tumour microenvironment characterisation to stratify patients for hyperthermic intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1)	28
Response to: Genetic risk scores may compound rather than solve the issue of prostate cancer overdiagnosis (BJC-LT3342090)	28
Artificial intelligence-driven microRNA signature for early detection of gastric cancer: discovery and clinical functional exploration	27
Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis	27
Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies	27
Understanding genetic architecture of breast cancer: how can proteome-wide association studies contribute?	27
Genome-wide polygenic risk scores for colorectal cancer have implications for risk-based screening	27
Attention-based deep learning for breast lesions classification on contrast enhanced spectral mammography: a multicentre study	27
Angiogenin and plexin-B2 axis promotes glioblastoma progression by enhancing invasion, vascular association, proliferation and survival	27
Correction: DKC1 enhances angiogenesis by promoting HIF-1α transcription and facilitates metastasis in colorectal cancer	27
A combination of intrinsic and extrinsic features improves prognostic prediction in malignant pleural mesothelioma	27
Prognostic value of post-operative iron biomarkers in colorectal cancer: population-based patient cohort	27
Prognostic relevance of HRDness gene expression signature in ovarian high-grade serous carcinoma; JGOG3025-TR2 study	26
Hypoxia-inducible factor 3α1 increases epithelial-to-mesenchymal transition and iron uptake to drive colorectal cancer liver metastasis	26
ctDNA variations according to treatment intensity in first-line metastatic colorectal cancer	26
AKT/mTOR as a targetable hub to overcome multimodal resistance to EGFR inhibitors in oesophageal squamous cell carcinoma	26
Regulatory T cells induce a suppressive immune milieu and promote lymph node metastasis in intrahepatic cholangiocarcinoma	26
Hormone replacement therapy and cancer mortality in women with 17 site-specific cancers: a cohort study using linked medical records	26
Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells	25
Epithelial−mesenchymal transition induced by tumor cell-intrinsic PD-L1 signaling predicts a poor response to immune checkpoint inhibitors in PD-L1-high lung cancer	25
Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2	25
Natural immunity to SARS-CoV-2 and breakthrough infections in vaccinated and unvaccinated patients with cancer	25
Targeting the untargetable: RB1-deficient tumours are vulnerable to Skp2 ubiquitin ligase inhibition	25
Targeting serine/glycine metabolism improves radiotherapy response in non-small cell lung cancer	25
A study of subjective memory impairment in long-term testicular cancer survivors	25
Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer	25
Multicentric validation of diagnostic tests based on BC-116 and BC-106 urine peptide biomarkers for bladder cancer in two prospective cohorts of patients	25
Anti-angiogenic therapy using the multi-tyrosine kinase inhibitor Regorafenib enhances tumor progression in a transgenic mouse model of ß-cell carcinogenesis	25
Role of 18F-FDG-PET/CT in the initial staging of very high-risk Ewing Sarcoma in a prospective multicentric Phase II Study: Is there still a place for bone marrow sampling?	25
Exploiting mesothelin in thymic carcinoma as a drug delivery target for anetumab ravtansine	25
Long-term activation of anti-tumor immunity in pancreatic cancer by a p53-expressing telomerase-specific oncolytic adenovirus	24
Breast density is strongly associated with multiparametric magnetic resonance imaging biomarkers and pro-tumorigenic proteins in situ	24
Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers	24
Breast cancer metastasis progression is associated with elevated activity of kynurenine monooxygenase and kynureninase	24
Intratumour heterogeneity, from hypothesis to the clinic	24
The long noncoding RNA lncZBTB10 facilitates AR function via S-palmitoylation to promote prostate cancer progression and abiraterone resistance	24
Modelled mortality benefits of multi-cancer early detection screening in England	24
Comment on: “Neoadjuvant chemotherapy is noninferior to chemoradiotherapy for early-onset locally advanced rectal cancer in the FOWARC trial”	24
Mutational signature profiling classifies subtypes of clinically different mismatch-repair-deficient tumours with a differential immunogenic response potential	24
Associations between serum glucose, insulin, insulin resistance and the risk of incident primary liver cancer or chronic liver disease mortality: a nested case–control study	24
Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy	24
Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer	23
Adherence to the World Cancer Research Fund/American Institute for Cancer Research cancer prevention recommendations throughout the life course and risk of colorectal cancer precursors	23
A liquid biopsy signature for predicting early recurrence in patients with gastric cancer	23
Editorial Expression of Concern: Upregulation of p27 and its inhibition of CDK2/cyclin E activity following DNA damage by a novel platinum agent are dependent on the expression of p21	23
Personalised circulating tumour DNA assay with large-scale mutation coverage for sensitive minimal residual disease detection in colorectal cancer	23
Multicenter evaluation of breast cancer patients’ satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic	23
Platelets induce CD39 expression in tumor cells to facilitate tumor metastasis	23
HeLa cells cross-contaminated nasopharyngeal carcinoma cell lines: Still a common problem	23
Anthropometric traits and risk of multiple myeloma: differences by race, sex and diagnostic clinical features	23
Clinical assessment of the miR-34, miR-200, ZEB1 and SNAIL EMT regulation hub underlines the differential prognostic value of EMT miRs to drive mesenchymal transition and prognosis in resected NSCLC	23
Multi-omics mapping of human papillomavirus integration sites illuminates novel cervical cancer target genes	23
Trajectories of α-fetoprotein and unresectable hepatocellular carcinoma outcomes receiving atezolizumab plus bevacizumab: a secondary analysis of IMbrave150 study	23
Peripheral blood neutrophils contribute to Claudin18.2-specific CAR-T cell treatment resistance in advanced gastric cancer	23
Semi-mechanistic efficacy model for PARP + ATR inhibitors—application to rucaparib and talazoparib in combination with gartisertib in breast cancer PDXs	23
LHX2 facilitates the progression of nasopharyngeal carcinoma via activation of the FGF1/FGFR axis	23
IL-10RA governor the expression of IDO in the instruction of lymphocyte immunity	23
Phase I study of procaspase-activating compound-1 (PAC-1) in the treatment of advanced malignancies	23
PRRX1-TOP2A interaction is a malignancy-promoting factor in human malignant peripheral nerve sheath tumours	23
Graph machine learning for integrated multi-omics analysis	22
Evolving roles of CD38 metabolism in solid tumour microenvironment	22
Correction: E2F7−EZH2 axis regulates PTEN/AKT/mTOR signalling and glioblastoma progression	22
Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists	22